COMP <GO>
SPTX vs MNKD // EV/EBITDA & P/E VALUATION
Seaport Therapeutics Inc. (NASDAQ) VS. MannKind Corporation (NASDAQ) • 15-METRIC TALLY: SPTX 1
— MNKD 1
■ METRIC PARITY
LAST: $21.10 (+3.53%) • MKT CAP: $1.13B
valuation
—
LAST: $3.50 (+2.04%) • MKT CAP: $1.13B
valuation
24.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPTX VS. MNKD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPTX | MNKD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 92.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 54.50% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 24.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 1.22% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 11.10% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 1.70% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 22.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 55.6 | -6.93 | MNKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.13B | $1.13B | $4.1M | SPTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPTX REV | MNKD REV | SPTX GROSS % | MNKD GROSS % | SPTX FCF | MNKD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $349.0M | — | 92.3% | — | $13.7M |
| FY 2024 | — | $285.5M | — | 93.9% | — | $32.8M |
| FY 2023 | — | $199.0M | — | — | — | $34.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPTX // BETA —
MNKD // BETA —